Clinical trials: Breast Neoplasms, Male
Solid Tumor
Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1
The purpose of this study is assess the safety of administering repeated doses of IMF-001, a vaccine, to patients with solid tumors that express NY-ESO-1 antigen.
- Trial name
- NCT01234012
- Testing
- IMF-001
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- ImmunoFrontier, Inc.
Cancer
Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection
RATIONALE: Heparin or M-EDTA may prevent catheter-related infections and blockages in patients at high risk for a catheter-related infection.
- Trial name
- NCT00378781
- Testing
- Heparin, Minocycline-EDTA
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Lung Cancer
Axelopran for Advanced Cancer in Patients Receiving Opioids
The primary objective of this single arm, open label, phase II trial is to determine if axelopran use impacts cancer control in patients with advanced cancers of the lung, breast, pancreas, and prostate.
- Conditions
- Breast Cancer, Lung Cancer, Pancreas Cancer, Prostate Cancer
- Trial name
- AxeCan (NCT07354919)
- Testing
- axelopran
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- HealthPartners Institute
Breast Cancer, Colorectal Cancer
Geriatric Assessment and Promotores (GAP) Pilot Feasibility Study
The goal of this clinical trial is to test a new way to help older adults who have had cancer. The researchers want to see if a program that assesses participants health and aging is achievable and makes a difference.
- Conditions
- Breast Cancer, Colorectal Cancer, Prostate Cancer
- Trial name
- GAP (NCT06125145)
- Testing
- Geriatric Assessment and Promotora Coaching
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, Davis
Breast Cancer, Familial Male, Radiotherapy; Complications
Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer
Radiation therapy is a crucial part in the comprehensive treatment of breast cancer. In recent years, emerging systemic treatment regimens such as HER 2 inhibitors, CDK 4/6 inhibitors, PARP inhibitors, capecitabine and PD1…
- Conditions
- Breast Cancer, Familial Male, Radiotherapy; Complications, Chemotherapeutic Toxicity, Immune Checkpoint Inhibitor
- Trial name
- RADIOCOM (NCT06197581)
- Testing
- Chest wall / breast radiation with or without lymph node region radiation.(For all of the enrolled patients)
- Where
- China
- Volunteers
- 148 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Breast Cancer
GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu
RATIONALE: GW572016 may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing…
- Trial name
- NCT00085020
- Testing
- trastuzumab, lapatinib ditosylate
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Bone Metastases, Breast Cancer
Safety and Efficacy Study of Concomitant Radiotherapy and Zoledronic Acid for Bone Metastases Palliation
Zoledronic acid (Zometa) belongs to a class of drugs called bisphosphonates. Bisphosphonates are used in bone metastases to keep the cancerous lesion under control in the bone and to help prevent calcium level elevations in the…
- Conditions
- Bone Metastases, Breast Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT00264420
- Testing
- zoledronic acid
- Volunteers
- 4 people
- Sponsor
- The Cleveland Clinic
Breast Cancer, Chronic Myeloproliferative Disorders
Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation
RATIONALE: White blood cells from donors may be able to kill cancer cells in patients with cancer that has recurred following bone marrow or peripheral stem cell transplantation.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer
- Trial name
- NCT00003887
- Testing
- peripheral blood lymphocyte therapy
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Breast Neoplasms, Lung Neoplasms
Benchmarking Large Language Models Against Tumour Boards for Oncology Treatment Recommendations
BEACON (Benchmarking AI for Clinical Oncology decisioNmaking) is a prospective, multicentre, comparative, blinded, non-interventional benchmark comparing the treatment recommendations of six frontier large language models (LLMs)…
- Conditions
- Breast Neoplasms, Lung Neoplasms, Urologic Neoplasms, Prostatic Neoplasms
- Trial name
- BEACON (NCT07739121)
- Testing
- Multidisciplinary tumour boards, Frontier large language models
- Where
- 5 sites in France
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Brain Cancer, Breast Cancer
18-F-Fluoroacetate as PET Imaging Agent
The goal of this clinical research study is to find out the highest tolerable dose of an imaging solution called 18-F-fluoroacetate sodium that can be given before a positron emission tomography (PET) scan.
- Conditions
- Brain Cancer, Breast Cancer, Prostate Cancer
- Trial name
- NCT01320787
- Testing
- 18F-fluoroacetate
- Sponsor
- M.D. Anderson Cancer Center
Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of PI3Kbeta inhibitor AZD8186 when given together with docetaxel in treating patients with solid tumors with PTEN or PIK3CB mutations that have spread to other places in…
- Conditions
- Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Prostate Carcinoma, Anatomic Stage III Breast Cancer AJCC v8
- Trial name
- NCT03218826
- Testing
- Docetaxel, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 8 sites in United States
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Radiolabeled Monoclonal Antibody Followed by Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Metastatic Breast Cancer
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00020410
- Testing
- filgrastim, peripheral blood stem cell transplantation, yttrium Y 90 monoclonal antibody B3
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Prostate Cancer
4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases
The current Rethinking Clinical Trials (REaCT) trial will compare two schedules(12- vs. 4-weekly) of bone-targeting agents (BTAs) to evaluate quality of life, pain and skeletal events within the Canadian Health Care System.
- Conditions
- Breast Cancer, Prostate Cancer, Metastasis
- Trial name
- REaCT-BTA (NCT02721433)
- Testing
- Pamidronate, Denosumab, Zoledronate
- Where
- Canada
- Volunteers
- 263 people
- Sponsor
- Ottawa Hospital Research Institute
Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer
Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer
This trial will facilitate access to denosumab for adults with advanced cancer who have participated in a denosumab phase 3 study until denosumab is approved and available for sale.
- Trial name
- NCT01419717
- Testing
- Denosumab
- Where
- 64 sites in Argentina, Austria and 17 more
- Volunteers
- 129 people
- Sponsor
- Amgen
Breast Cancer, Ovarian Cancer
Investigating the Diagnostic Potential of Tear Proteins in Cancer - A Pilot Study
This Pilot Study is to investigate the tear proteins in a multitude of cancer types and indulge in biomarker discovery to manufacture simple, accurate, and novel tear-based diagnostic tests.
- Conditions
- Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer
- Trial name
- NCT05223218
- Testing
- Schirmer strip, a Class I Medical Device typically used to test for dry eye.
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Namida Lab
Prostatic Neoplasms, Breast Cancer
Study With Modafinil in Patients Treated With Docetaxel-Based Chemotherapy for Metastatic Breast or Prostate Cancer (MOTIF)
The primary objective is: To determine the efficacy of modafinil in the reduction of fatigue in patients with metastatic breast or prostate cancer undergoing docetaxel-based chemotherapy The secondary objectives are: To determine…
- Trial name
- NCT00917748
- Testing
- DOCETAXEL(XRP6976) + MODAFINIL, Modafinil
- Where
- Australia
- Volunteers
- 84 people
- Sponsor
- Sanofi
Breast Cancer, Liver Cancer
Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials
This proposal brings together multidisciplinary teams from four New York City institutions charged with reducing cancer disparities that affect approximately two million people residing in some of the most diverse and underserved…
- Conditions
- Breast Cancer, Liver Cancer, Prostate Cancer
- Trial name
- DISRUPT (NCT05146297)
- Testing
- Clinical trial match-list, Match-list intervention
- Where
- 3 sites in United States
- Volunteers
- 585 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Breast Cancer
Radiolabeled Monoclonal Antibody Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Breast Cancer
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00007891
- Testing
- filgrastim, autologous bone marrow transplantation, peripheral blood stem cell transplantation
- Where
- 2 sites in United States
- Sponsor
- Cancer Research Institute of Contra Costa
Breast Cancer
Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer
RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells. Giving vaccine therapy together with QS21 may cause a stronger immune response and kill more tumor cells.
- Trial name
- NCT00470574
- Testing
- QS21, sialyl Lewisª-keyhole limpet hemocyanin conjugate vaccine, immunoenzyme technique
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast - Female, Breast - Male
Molecular and Cellular Analysis of Breast Cancer
The purpose of the study is to investigate the different types and subtypes of cells found in breast tumors. The investigators will do this using a variety of molecular analysis tools that may allow for improved tests.
- Trial name
- NCT02243397
- Where
- United States
- Volunteers
- 145 people
- Sponsor
- Stanford University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.